We narrowed to 18,888 results for: REV

#140135-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#140136-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Oct. 28, 2021

Academic Institutions and Nonprofits only

#140135-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#140136-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iDreV (#140136). In addition to the viral particles, you will also receive purified pAAV-EF1a-iDreV plasmid DNA. EF1a-driven, light-inducible iDreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Nov. 29, 2021

Academic Institutions and Nonprofits only

#52536-AAV1

Ready-to-use AAV1 particles produced from rAAV-CAG::FLEX-rev:: hM4D-2a-GFP (#52536). In addition to the viral particles, you will also receive purified rAAV-CAG::FLEX-rev:: hM4D-2a-GFP plasmid DNA. CAG driven, Cre-dependent expression of hM4D and GFP. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al Nature. 2012 Aug 9;488(7410):172-7. doi:

Dec. 18, 2024

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#161769

Tet-inducible inhibition library targeting the yeast genome with barcode linked guide RNAs.

Nicholas Ingolia

McGlincy et al BMC Genomics. 2021 Mar 23;22(1):205. doi

Nov. 30, 2021

Academic Institutions and Nonprofits only